Evidence map›Paper›PMID 40453491›Full record

ArticleFrontiers in public health2025

REVIRAL: roadmap for the elimination of viral hepatitis in Latin America.

Javier Crespo, Joaquín Cabezas, Graciela Castro-Narro, Hugo Cheinquer, Fernando Contreras, Nelia Hernandez, Christie Perelló, Ezequiel Ridruejo, José Luís Calleja

Abstract read
In one paragraph

Article in Frontiers in public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Javier CrespoGastroenterology and Hepatology Department, University Hospital Marqués de Valdecilla, Santander, Spain.
Joaquín CabezasGastroenterology and Hepatology Department, University Hospital Marqués de Valdecilla, Santander, Spain.
Graciela Castro-NarroGastroenterology and Hepatology Department, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de México, Mexico.
Hugo CheinquerGastroenterology and Hepatology Department, Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.
Fernando ContrerasCentro de Gastroenterología Avanzada de Santo Domingo, Santo Domingo, Dominican Republic.
Nelia HernandezGastroenterology and Hepatology Department, Hospital de Clínicas, Facultad de Medicina, Universidad de la Republica, Montevideo, Uruguay.
Christie PerellóGastroenterology and Hepatology Department, Puerta de Hierro University Hospital, Madrid, Spain.
Ezequiel RidruejoHepatology Section, Department of Medicine, Centro de Educación Médica e Investigaciones Clínicas Norberto Quirno "CEMIC", Buenos Aires, Argentina.
José Luís CallejaGastroenterology and Hepatology Department, Puerta de Hierro University Hospital, Madrid, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The REVIRAL project proposes a comprehensive and tailored strategy for the elimination of viral hepatitis in Latin America, drawing inspiration from successful models in other countries. Despite global advances, the region faces specific barriers, including the lack of universal screening programs, disparities in access to direct-acting antiviral treatments, the presence of fragmented health systems, and the social stigma associated with these infections. These factors hinder progress towards elimination, necessitating collaborative responses tailored to the epidemiological and socioeconomic realities of each country. The project's structure is organized into three fundamental phases: The first phase involves an initial assessment, where the epidemiological situation of each country will be analyzed, specifically the prevalence and incidence data of viral hepatitis and the response capacity of each country's health systems. This phase will also identify specific barriers, allowing interventions to be adjusted to local needs. The second phase will focus on the implementation of intervention programs, promoting universal screening, strengthening healthcare personnel training, and implementing health models that enhance linkage-to-care. The third phase will concentrate on monitoring and evaluating results through a global elimination marker, designed to measure and compare progress across countries. The success of REVIRAL will largely depend on the commitment of local governments and international cooperation. If implemented correctly, the project could transform the public health response to viral hepatitis in Latin America and serve as a replicable model for other regions with similar challenges advancing toward the WHO's global elimination goals set for 2030.

Indexed as

Disease EradicationHepatitis, Viral, HumanHumansLatin AmericaMass ScreeningPrevalenceeliminationepidemiologylinkage-to-caremodels of careviral hepatitis

Identifiers

PMID40453491
PMCPMC12123641

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.